InnoCare Pharma prepares $300m Hong Kong IPO

By Jonathan Breen
02 Mar 2020

Chinese biotechnology company InnoCare Pharma has won final approval for its Hong Kong IPO. The next step is marketing the deal, after delayed investor meetings in February.

The issuer, backed by Singapore sovereign wealth fund GIC, is working with Goldman Sachs and Morgan Stanley to market its listing, which could reportedly raise up to $300m.

But the outbreak of the novel coronavirus, Covid-19, has reduced most roadshows to virtual interaction, with banks advising against ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial